Table 9.
Brain and Central Nervous System Tumor Average Annual Age–Adjusted Incidence Rates† by Major Histology Groupings, Histology and Gender, CBTRUS Statistical Report: NPCR and SEER, 2005–2009
| Histology | Total |
Male |
Female |
|||
|---|---|---|---|---|---|---|
| Rate | 95% CI | Rate | 95% CI | Rate | 95% CI | |
| Tumors of Neuroepithelial Tissue | 6.60 | (6.56–6.64) | 7.77 | (7.70–7.84) | 5.59 | (5.54–5.64) |
| Pilocytic astrocytoma | 0.33 | (0.32–0.34) | 0.33 | (0.32–0.34) | 0.32 | (0.31–0.34) |
| Diffuse astrocytoma | 0.58 | (0.57–0.60) | 0.68 | (0.66–0.70) | 0.50 | (0.48–0.52) |
| Anaplastic astrocytoma | 0.36 | (0.35–0.37) | 0.43 | (0.42–0.45) | 0.30 | (0.28–0.31) |
| Unique astrocytoma variants | 0.07 | (0.06–0.07) | 0.07 | (0.06–0.08) | 0.06 | (0.06–0.07) |
| Glioblastoma | 3.19 | (3.16–3.22) | 3.98 | (3.94–4.03) | 2.53 | (2.49–2.56) |
| Oligodendroglioma | 0.27 | (0.26–0.28) | 0.30 | (0.29–0.31) | 0.24 | (0.23–0.25) |
| Anaplastic oligodendroglioma | 0.11 | (0.11–0.12) | 0.13 | (0.12–0.14) | 0.10 | (0.09–0.11) |
| Oligoastrocytic tumors | 0.21 | (0.20–0.21) | 0.24 | (0.23–0.25) | 0.18 | (0.17–0.19) |
| Ependymal tumors | 0.41 | (0.40–0.42) | 0.46 | (0.45–0.48) | 0.37 | (0.35–0.38) |
| Glioma malignant, NOS | 0.45 | (0.44–0.46) | 0.48 | (0.46–0.49) | 0.43 | (0.41–0.44) |
| Choroid plexus tumors | 0.05 | (0.05–0.06) | 0.05 | (0.05–0.06) | 0.05 | (0.05–0.06) |
| Other neuroepithelial tumors | 0.01 | (0.01–0.01) | 0.01 | (0.00–0.01) | 0.01 | (0.01–0.01) |
| Neuronal and mixed neuronal–glial tumors | 0.27 | (0.26–0.28) | 0.29 | (0.28–0.30) | 0.25 | (0.24–0.26) |
| Tumors of the pineal region | 0.04 | (0.04–0.04) | 0.03 | (0.03–0.04) | 0.05 | (0.04–0.05) |
| Embryonal tumors | 0.26 | (0.25–0.27) | 0.29 | (0.28–0.31) | 0.22 | (0.21–0.24) |
| Tumors of Cranial and Spinal Nerves | 1.70 | (1.68–1.73) | 1.70 | (1.67–1.73) | 1.71 | (1.69–1.74) |
| Nerve sheath tumors | 1.70 | (1.68–1.72) | 1.70 | (1.67–1.73) | 1.71 | (1.68–1.74) |
| Other tumors of cranial and spinal nerves | 0.00 | (0.00–0.00) | – | – | – | – |
| Tumors of Meninges | 7.49 | (7.45–7.54) | 4.58 | (4.53–4.63) | 10.00 | (9.93–10.07) |
| Meningioma | 7.22 | (7.18–7.27) | 4.28 | (4.23–4.33) | 9.76 | (9.69–9.83) |
| Mesenchymal tumors | 0.08 | (0.08–0.09) | 0.08 | (0.08–0.09) | 0.08 | (0.07–0.09) |
| Primary melanocytic lesions | 0.01 | (0.01–0.01) | 0.01 | (0.01–0.01) | 0.01 | (0.00–0.01) |
| Other neoplasms related to the meninges | 0.18 | (0.17–0.19) | 0.21 | (0.20–0.22) | 0.16 | (0.15–0.17) |
| Lymphomas and Hemopoietic Neoplasms | 0.46 | (0.45–0.47) | 0.54 | (0.52–0.55) | 0.40 | (0.38–0.41) |
| Lymphoma | 0.45 | (0.44–0.46) | 0.52 | (0.51–0.54) | 0.39 | (0.37–0.40) |
| Other hemopoietic neoplasms | 0.01 | (0.01–0.01) | 0.01 | (0.01–0.02) | 0.01 | (0.01–0.01) |
| Germ Cell Tumors and Cysts | 0.10 | (0.09–0.10) | 0.13 | (0.12–0.14) | 0.06 | (0.06–0.07) |
| Germ cell tumors, cysts and heterotopias | 0.10 | (0.09–0.10) | 0.13 | (0.12–0.14) | 0.06 | (0.06–0.07) |
| Tumors of Sellar Region | 3.12 | (3.09–3.15) | 2.96 | (2.92–3.00) | 3.36 | (3.32–3.41) |
| Tumors of the pituitary | 2.94 | (2.91–2.97) | 2.78 | (2.74–2.81) | 3.18 | (3.14–3.22) |
| Craniopharyngioma | 0.18 | (0.18–0.19) | 0.18 | (0.17–0.19) | 0.18 | (0.17–0.19) |
| Unclassified Tumors | 1.12 | (1.10–1.13) | 1.12 | (1.10–1.15) | 1.12 | (1.10–1.14) |
| Hemangioma | 0.22 | (0.21–0.23) | 0.20 | (0.19–0.21) | 0.23 | (0.22–0.25) |
| Neoplasm, unspecified | 0.89 | (0.88–0.91) | 0.92 | (0.89–0.94) | 0.88 | (0.86–0.90) |
| All other | 0.01 | (0.01–0.01) | 0.01 | (0.01–0.01) | 0.01 | (0.00–0.01) |
| Total‡ | 20.59 | (20.52–20.66) | 18.80 | (18.69–18.90) | 22.25 | (22.15–22.35) |
† Rates are per 100,000 and are age–adjusted to the 2000 US standard population.
‡ Refers to all brain tumors including histologies not presented in this table.
– Counts are not presented when fewer than 16 cases were reported for the specific histology category. Suppressed cases are included in the total count.
Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NPCR, CDC's National Program of Cancer Registries; SEER, NCI's Surveillance, Epidemiology and End Results program; CI, confidence interval; NOS, not otherwise specified.